anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: A prototype lateral flow device detecting cytokine biomarkers interleukin (IL)-1α and IL-1β has been developed as a point-of-care test-called the Genital InFlammation Test (GIFT)-for detecting genital inflammation associated with sexually transmitted infections (STIs) and/or bacterial vaginosis (BV) in women. In this paper, we describe the rationale and design for studies that will be conducted in South Africa, Zimbabwe and Madagascar to evaluate the performance of GIFT and how it could be integrated into routine care.
METHODS AND ANALYSIS: We will conduct a prospective, multidisciplinary, multicentre, cross-sectional and observational clinical study comprising two distinct components: a biomedical ('diagnostic study') and a qualitative, modelling and economic ('an integration into care study') part. The diagnostic study aims to evaluate GIFT's performance in identifying asymptomatic women with discharge-causing STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV) and Mycoplasma genitalium (MG)) and BV. Study participants will be recruited from women attending research sites and family planning services. Several vaginal swabs will be collected for the evaluation of cytokine concentrations (ELISA), STIs (nucleic acid amplification tests), BV (Nugent score) and vaginal microbiome characteristics (16S rRNA gene sequencing). The first collected vaginal swab will be used for the GIFT assay which will be performed in parallel by a healthcare worker in the clinic near the participant, and by a technician in the laboratory. The integration into care study aims to explore how GIFT could be integrated into routine care. Four activities will be conducted: user experiences and/or perceptions of the GIFT device involving qualitative focus group discussions and in-depth interviews with key stakeholders; discrete choice experiments; development of a decision tree classification algorithm; and economic evaluation of defined management algorithms.
ETHICS AND DISSEMINATION: Findings will be reported to participants, collaborators and local government for the three sites, presented at national and international conferences, and disseminated in peer-reviewed publications.The protocol and all study documents such as informed consent forms were reviewed and approved by the University of Cape Town Human Research Ethics Committee (HREC reference 366/2022), Medical Research Council of Zimbabwe (MRCZ/A/2966), Comité d'Ethique pour la Recherche Biomédicale de Madagascar (N° 143 MNSAP/SG/AMM/CERBM) and the London School of Hygiene and Tropical Medicine ethics committee (LSHTM reference 28046).Before the start, this study was submitted to the Clinicaltrials.gov public registry (NCT05723484).
TRIAL REGISTRATION NUMBER: NCT05723484.
At least one primary healthcare centre per ward and one General Hospital per selected LGA (in 50% of LGAs in each of the 3 states) and one secondary hospital per State will be contracted by the State Primary Health Care Development Agency ) , to deliver specified services at an agreed price. Selection of which services to focus on is based on priorities identified by the Federal Government of Nigeria and the states in 2010-2015. Initial prices for each service were based on shadow prices of providing the service and have been adjusted based on implementation experience.
The invention relates to a new traditional Chinese medicine compound preparation for treating migraine as well as a use method and application thereof, belonging to the technical field of traditional Chinese medicine. Migraine is a kind of recurrent primary headache, and 2.4 hundred million migraineurs exist all over the world. In China, the migraine morbidity rate is 985.2/100000 and the incidence of disease is 79.7/100000. At present, western medicine for treating migraine gives priority to treatment of acute attack, thus passably alleviating the symptoms but having poor effect on controlling recurrence. Traditional Chinese medicine has unique advantages in treating migraine, but traditional Chinese patent medicines for treating migraine at present are mainly Zhengtian Wan, Taiji Tongtian Oral Solution, ZhenNaoNing Capsule, Tianma Gouteng Granule, Chuanxiongchatiao Granule and Yangxueqingnao Granule, and a medicine aiming at the type of blood stasis due to cold accumulation is lacked. The new traditional Chinese medicine compound preparation is prepared by summarizing clinical experiences for many years and prescribing by selecting effective medicines, has good clinical curative effect on migraine (type of liver wind accompanied by blood stasis), and can cover the shortage of the existing traditional Chinese patent medicines for treating migraine.
Embodiments described herein include a method and system for updating, by a computing device, a data receiving device for an analyte sensor. The method includes receiving, by the computing device, an application update package that includes an update for an application installed on the computing device and a software or firmware update for the data receiving device. The application and software or firmware are configured to communicate with or process data from the analyte sensor. The method includes establishing, by the computing device, a short-range wireless communication session with the data receiving device. The method includes transmitting, by the computing device, a software or firmware update for the data receiving device to the data receiving device over a short-range wireless communication session with the data receiving device. The method includes receiving, by the computing device, a confirmation of installation of the software or firmware update by the data receiving device.
Following intravenous administrations of citalopram, the fraction of drug recovered in the urine as citalopram and DCT was about 10% and 5%, respectively. The systemic clearance of citalopram was 330 mL/min, with approximately 20% of that due to renal clearance.

Citalopram is metabolized to demethylcitalopram (DCT), didemethylcitalopram (DDCT), citalopram-N-oxide, and a deaminated propionic acid derivative. In humans, unchanged citalopram is the predominant compound in plasma. At steady state, the concentrations of citalopram's metabolites, DCT and DDCT, in plasma are approximately one-half and one-tenth, respectively, that of the parent drug. In vitro studies show that citalopram is at least 8 times more potent than its metabolites in the inhibition of serotonin reuptake, suggesting that the metabolites evaluated do not likely contribute significantly to the antidepressant actions of citalopram.

In vitro studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.
This study will test the efficacy of an intervention REDES ("Networks") - a social network intervention - to address COVID-19 vaccine hesitancy and uptake among a cohort of Latinos and networks. 300 index participants who have taken the COVID-19 vaccine will be recruited. Half of the index participants (n=150) will be randomized to the experimental group and will receive training on motivational interviewing to promote vaccine acceptance and uptake with networks. Index participants in the control group (n=150) will receive updated information about the COVID-19 vaccine. In addition, unvaccinated primary and secondary network members of indexes will be recruited for study participation and COVID-19 vaccination. All participants will be followed prospectively at 6, 12, and 18 months after baseline intake. The specific aims are: 1) Evaluate the efficacy of the REDES intervention to promote COVID-19 vaccine uptake among Latinos; 2) Examine ongoing barriers and facilitators of vaccine uptake among Latinos and networks to tailor the intervention and address new challenges, and 3) Evaluate the implementation determinants and outcomes of REDES to inform future broad-scale implementation.
The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composite used for treating cervical spondylosis and a preparing method thereof. The composite is prepared from, by weight, 45-55 parts of Radix Astragali, 13-23 parts of Cassia Twig, 15-25 parts of Rhizoma Et Radix Notopterygii, 15-25 parts of Radix Angelicae Pubescentis, 9-11 parts of Radix Paeoniae Alba, 2-5 parts of Herba Asari, 15-20 parts of Rhizoma Pinelliae, 4-14 parts of Radix Glycyrrhizae, 8-12 parts of Poria, 10-20 parts of Radix Puerariae, 5-15 parts of Flos Carthami, 8-10 parts of Chinese Angelica, 4-9 parts of Caulis Sinomenii, 15-25 parts of Radix Clematidis, 19-29 parts of Caulis Spatholobi and 15-25 parts of Herba Lycopodii. The composite used for treating cervical spondylosis has the advantages of high pertinency, good curative effect, short cycle, low price, no side effect and the like. The composite makes the patients accept with pleasure and can better treat cervical spondylosis. Various components in the composite synergize with each other for joint effect. And the medicine has easy preparation, quick effect, short course of treatment and good therapeutic action on cervical spondylosis.
Acute wounds are converted to chronic wounds due to advanced age and diabetic complications. Nanozymes catalyze ROS production to kill bacteria without causing drug resistance, while microneedles (MNs) can break through the skin barrier to deliver drugs effectively. Nanozymes can be intergrateded into MNs delivery systems to improve painless drug delivery. It can also reduce the effective dose of drug sterilization while increasing delivery efficiency and effectively killing wounded bacteria while preventing drug resistance. This paper describes various types of metal nanozymes from previous studies and compares their mutual enhancement with nanozymes. The pooled results show that the MNs, through material innovation, are able to both penetrate the scab and deliver nanozymes and exert additional anti-inflammatory and bactericidal effects. The catalytic effect of some of the nanozymes can also accelerate the lysis of the MNs or create a cascade reaction against inflammation and infection. However, the issue of increased toxicity associated with skin penetration and clinical translation remains a challenge. This study reviews the latest published results and corresponding challenges associated with the use of MNs combined with nanozymes for the treatment of wounds, providing further information for future research.
This study is a randomized, parallel-controlled, multicenter clinical study. We recruit patients over the age of 18 years with platinum-resistant recurrent ovarian cancer. patients who meet the criteria for enrollment are randomly divided into two groups, including experiment group and control group. This study will be divided into three stages: 1. Baseline period (within 21 days before the start of treatment): Patients will complete screening tests during the baseline period to assess whether they meet the selection criteria. 2. Treatment period (from the first administration to the completion of the last treatment cycle). The tumor will be evaluated every 8 weeks during this period. If the treatment is effective, the chemotherapy does not exceed 6 cycles，then experiment group receives oral apatinib maintenance therapy until the disease progresses or toxicity could not be tolerated. Control group is followed up. 3. Follow-up period. After the end of chemotherapy, the survival status and follow-up anti-tumor therapy are collected by telephone or research centers visit every 3 months until death or loss of follow-up.The primary endpoint is the progression-free survival time(PFS) of patients and is judged according to Response Evaluation Criteria in Solid Tumors, version 1.1. Adverse events are classified and recorded according to the National Cancer Institute's Standard of Common terms for adverse reactions (NCI-CTCAE) version 4.0.
Chloroleandomycin (chloramimycin antibiotic Chlor PA105) is obtained by bubbling anhydrous hydrogen chloride into a solution of oleandomycin in an organic solvent.  It may be used medicinally in admixture with one or more tetracyclines (see Group VI).ALSO:An antibiotic composition comprises oleandomycin and one or more tetracyclines, an antibiotic which increases the effectiveness of the eleandomycin.  The tetracycline may be oxytetracycline, chlortetracycline or tetracycline in the form of the ampholeric substance or in any therapeutic form, e.g. hydrochloride and other pharmaceutically effective salts with acids, and salts with metals such as sodium and potassium.  The oleandomycin may also be in any theraspeutic form, such as the free base, the hydrochloride, the phosphate and salts of other pharmaceutically acceptable acids. Oleandomycin may be replaced by chlor-oleandomycin (see Group IV (b)) as such or in the form of a salt with an acid such as the hydrochloride or phosphate.  The oleandomycin proportion of the total antibiotic content of the composition is 10 to 90 per cent and is preferably equal to or less than the proportion of tetracycline antibiotic in the composition.  The antibiotic may be in the crude state, the pure form or in a dilute form.  Therapeutic preparations are prepared by mixing the antibiotics with pharmaceutical carriers. Tablets and capsules may be prepared in which the diluents are starch, milk sugar and clay.  Injections are prepared with sterile solutions made isotonic with sodium chloride or glucose. Specifications 684,417, 690,381, [both in Group IV (b)], 747,779 and 779,257, [Group IV (b)], are referred to.
Systems and methods are provided for providing diabetes patient treatment guidance for a patient in which a biochemical data set is obtained. The biochemical data set comprises test results from a single blood draw of the patient including at least three measurements selected from the set: a high-sensitivity c-reactive protein test, an adiponectin level test, an intact proinsulin level test, an insulin level test, a C-peptide test, a HbA1c test, and an eGFR level test. A demographic data set for the patient is also obtained that comprises the patient's gender and diabetes stage. The biochemical data set and demographic data set is run against one or more rules to determine a first patient therapy pattern. Then, a report is prepared based on an identity of the first therapy patient pattern. The report sets priorities among intervention classes for the patient based on the identity of the first patient pattern.
In this randomized crossover trial, participants performed randomly assigned two experimental sessions: a beach tennis session and a non-exercise control session. The beach tennis session started with a standardized 5-minute warm-up consisting of basic techniques, followed by three 12-minute beach tennis matches with 2-minute intervals between them. Heart rate and rating of perceived exertion were continuously recorded during the beach tennis session, and enjoyment was measured after the beach tennis session. The control session was performed in seated rest. Both experimental sessions lasted 45 minutes. Ambulatory blood pressure was measured continuously for 24-hour after sessions.
BACKGROUND: Older adults with frailty have surgery at a high rate. Informal caregivers often support the postoperative transition in care. Despite the growing need for family and caregiver support for this population, little is known about the experience of providing informal care to older adults with frailty during the postoperative transition in care. The purpose of this study was to explore what is important during a postoperative transition in care for older adults with frailty from the perspective of informal caregivers.
METHODS: This was a qualitative study using an interpretive description methodology. Seven informal caregivers to older adults [aged ≥ 65 years with frailty (Clinical Frailty Scale score ≥ 4) who had an inpatient elective surgery] participated in a telephone-based, semi-structured interview. Audio files were transcribed and analyzed using reflexive thematic analysis.
RESULTS: Four themes were constructed: (1) being informed about what to expect after surgery; (2) accessible communication with care providers; (3) homecare resources are needed for the patient; and (4) a support network for the caregivers. Theme 4 included two sub-themes: (a) respite and emotional support and (b) occupational support.
CONCLUSIONS: Transitions in care present challenges for informal caregivers of older adults with frailty, who play an important role in successful transitions. Future postoperative transitional care programs should consider making targeted information, accessible communication, and support networks available for caregivers as part of facilitating successful transitions in care.
PURPOSE:To prepare a water-soluble proteinic anti-tumor substance having broad anti-tumor spectrum, high tumorigenesis-inhibiting activity, and high rate of complete recovery, by the separation and purification of a water extract of shellfish after removing the liver therefrom. CONSTITUTION:Liver is removed from shellfish such as turban shell, abalone, pearl oyster, etc., and the flesh of shellfish thus obtained is extracted with an aqueous medium. The extract is subjected to gel-filtration, ultra-filtration, etc. to afford an anti-tumor saccharide-containing protein having an average molecular weight of 10,000-30,000. The characteristics of the substance are as follows: white or slightly yellowish white solid; easily soluble to water; insoluble to organic solvents such as methanol, ethanol, chloroform, acetone, n-haxane, etc.; main peaks of IR spectrum, 1658 and 1550cm<-1>; positive to biuret reaction, xantoprotein reacttion, anthrone sulfuric acid reaction, cysteine sulfuric acid reaction; amphoteric electrolyte.
In patients who present with obstructing left-sided colorectal cancers, emergency surgery carries a significant morbidity and mortality. Traditionally, most of these patients would receive staged operations (Hartmann's procedure). Temporary stoma is often required due to the edematous bowel wall precluding primary anastomosis as a result of obstruction and the poor pre-morbid status. A second operation is subsequently required to restore bowel continuity. Apart from the expensive hospital costs of the staged operations, the patient's acceptance to the stoma is poor and the social inconvenience associated with the stoma is obvious. Thus, a significant portion of patients would not be suitable for the second operation due to poor health or advanced disease and having to bear the stoma for the remainder of life. Recently, self-expandable metal stents have been used with success in relieving the acute obstruction in patients with obstructing left-sided colorectal cancers. Endoscopic stenting may help to relieve the obstruction, avoid emergency surgery, and allows patients to undergo one-stage elective surgery without the necessity of making a stoma. We propose to evaluate the clinical benefits of using self-expandable metal stents in patients with obstructing left-sided colorectal cancers followed by elective laparoscopic resection and compare its use to immediate emergency surgery.
The experimental procedure for each participant assume random blind acute ingestion of CAFMIPS_2 in individual dose providing 3mg/kg BM of CAF at one of the study visits, which will be separated from other study visits with 7-days wash-out. The preparation will be provided in the form of powder and the individual doses of CAFMIPS_2 will be dissolved in 200 mL of water. The test preparation will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
1.A kit for carrying out retrovirus-mediated gene transfer into target cells, which comprises: (a) an effective amount of a functional material having retrovirus binding domain and/or an effective amount of another functional material having target cell binding domain; (b) an artificial substrate for incubating the retrovirus and the target cells; and (c) a target cell growth factor for pre-stimulating the target cells. 2. A kit according to claim 1, wherein the functional material is selected from Heparin-II binding region of fibronectin, fibroblast growth factors, collagens, polylysines and functional equivalents thereof. 3. A kit according to claim 1, wherein the functional material is a ligand which specifically binds to the correspondent target cells. 4. A kit according to claim 3, wherein the ligand is selected from cell adhesion proteins, hormones, cytokines, antibodies. 5. A kit according to claim 4, wherein the cell adhesion protein is a cell binding domain polypeptide of fibronectin. 6. A kit according to claim 5, wherein the cell binding domain polypeptide of fibronectin is a polypeptide of the binding domain to VLA-5 and/or VLA-4. 7. A kit according to claim 4, wherein the ligand is erythropoietin. 8. A kit according to any one of claims 1-7, wherein the functional materials are immobilized. 9. A kit according to claim 4, wherein the functional material is immobilized on beads. 10. A kit for carrying out retrovirus-mediated gene transfer into target cells, which comprises: (a) an effective amount of a functional material having a target cell binding domain, and a retrovirus binding domain derived from a fibroblast growth factor, a collagen or a polylysine, or a functional equivalent thereof on the same molecule; (b) an artificial substrate for incubating the retrovirus and the target cells; and (c) a target cell growth factor for pre-stimulating the target cells. 11. A kit according to claim 10, wherein the fibroblast growth factor is selected from a fragment comprising fibroblast growth factor with an amino acid sequence represented by SEQ. ID No. 3 of the Sequence Listing, functional equivalents of the factor and polypeptides containing the factor or functional equivalent of the factor. 12. A kit according to claim 10, wherein the functional material is a polypeptide having an amino acid sequence represented by SEQ. ID No. 4 or 5 of the Sequence Listing. 13. A kit according to claim 10, wherein the collagen is selected from a fragment having insulin binding domain derived from type V collagen, functional equivalents of the fragment and polypeptides containing the fragment or functional equivalents of the fragment. 14. A kit according to claim 13, wherein the fragment having insulin binding domain derived from type V collagen is a fragment having an amino acid sequence represented by SEQ. ID No. 6 of the Sequence Listing. 15. A kit according to claim 10, wherein the functional material is a polypeptide having an amino acid sequence represented by SEQ. ID No. 7 or 8 of the Sequence Listing. 16. A kit according to any one of claims 10-15, wherein the functional material is immobilized.
Participants randomized to Brief Screening For PTSD, screening will be conducted as part of regular clinic activities during the initial prenatal care visit. Specifically, clinic staff (nurse, PA) or study staff will ask the questions in the PC-PTSD-5 along with the standard procedure to administer the Edinburgh Postnatal Depression Scale (EPDS), and the provider will review the results with the patient during the prenatal care visit and provide referral resources regardless of screen outcome. Positive PTSD screens (PC-PTSD-5 ≥ 3) will be referred to the hospital's integrated care team following the same model as positive EPDS screens.